💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇻🇳 Tiếng Việt

Enfortumab Vedotin

CHEMBL3301589 Phase 4 Đã phê duyệt Antibody drug conjugate
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

This antibody-drug conjugate uses an antibody to deliver a cell-killing chemotherapy drug directly to cancer cells that carry a specific protein on their surface. It is used to treat urothelial cancer and other solid tumors.

Lĩnh vực điều trị

Bladder Cancer Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This antibody-drug conjugate uses an antibody to deliver a cell-killing chemotherapy drug directly to cancer cells that carry a specific protein on their surface. It is used to treat urothelial cancer and other solid tumors.

Yes, Enfortumab Vedotin is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301589. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.